Immix Biopharma: Tissue-Specific Therapeutics Developer Files For IPO Seeking Alpha / Avisol Capital Partners Sep. 28, 2021 2:12 PM ET Immix Biopharma, Inc. (IMMX) Summary Immix Biopharma is developing Tissue-Specific Therapeutics in oncology and inflammation with a Tumor Micro-Environment Normalization technology.The Company’s lead candidate has shown […]
Oncology biotech Immix Biopharma files for a $25 million IPO Renaissance Capital September 17, 2021 Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, filed on Friday with the SEC to raise up to $25 million in an initial public offering. Immix is […]
Newsletters – Term Sheet – IPOs Fortune September 17, 2021 “Immix Biopharma, a Los Angeles-based oncology drug company, filed for an initial public offering …” Original Article Link
BeiGene and Immix ink collaboration agreement for IMX-110/tislelizumab cancer study Seeking Alpha Aug. 27, 2021 8:47 AM ET By: Aakash Babu, SA News Editor     BeiGene (NASDAQ:BGNE) and Immix Biopharma announce a clinical trial and supply agreement to evaluate the safety, tolerability and efficacy of a […]
Immix Biopharma submits registration statement for IPO Seeking Alpha Jul. 23, 2021 11:11 AM ET By: Jonathan M Block, SA News Editor Immix Biopharma has confidentially submitted a draft registration statement (S-1 form) for an initial public offering. The number of shares to be offered and […]
West LA-Based Biotech ImmixBio – Maker of Cancer Treatments – Files for an IPO dot.la Keerthi Vedantam 03:52 PM | July 23, 2021 ImmixBio, a West L.A.-based startup developing cancer therapies, announced on Friday it submitted a confidential filing to go public. Ilya Rachman, chief executive […]
FierceBiotech FireceBiotech Chutes & Ladders Jul 9, 2021 9:30am “Immix Bio, focused on tissue-specific therapeutics for oncology and inflammation, chose Gabriel Morris as its chief financial officer and board member.” Original Article Link